Anti-EGFRvIII-CAR |
EGFRvIII CAR; Anti-EGFRvIII-CAR |
Phase 2 Clinical |
National Cancer Institute |
Glioblastoma; Brain Neoplasms; Gliosarcoma; Glioma |
Details
|
Recombinant anti-EGFR chimeric monoclonal antibody (Shanghai CP Guojian) |
CPGJ-602; 602; CPGJ602; CPGJ 602 |
Phase 2 Clinical |
Sunshine GuoJian Pharmaceutical (Shanghai) Co Ltd |
Colorectal Neoplasms |
Details
|
WSD-0922 |
WSD-0922; WSD0922 |
Phase 1 Clinical |
Wayshine Biopharm International Ltd |
Glioblastoma; Neoplasms; Astrocytoma; Carcinoma, Non-Small-Cell Lung |
Details
|
EGFRvIII-directed CAR-T cell tharapy (Novartis/University of Pennsylvania) |
LXF-821 |
Phase 1 Clinical |
University Of Pennsylvania, Novartis Pharma Ag |
Glioblastoma |
Details
|
EGFRvIII-CAR |
|
Phase 1 Clinical |
Duke University Medical Center |
Glioblastoma |
Details
|
Autologous Anti-EGFRvIII synNotch Receptor Induced Anti-EphA2/IL-13R alpha2 CAR (E-SYNC) T Cells therapy(California Institute For Regenerative Medicine) |
|
Phase 1 Clinical |
California Institute For Regenerative Medicine, National Cancer Institute |
Glioblastoma |
Details
|
Targeted EGFRvIII autochimeric antigen receptor T cell therapy (DCTY) |
DCTY0801; DCTY-0801 |
Phase 1 Clinical |
Beijing DCTY Biotech Co Ltd |
Glioblastoma |
Details
|
SNC-109 |
SNC109; SNC-109 |
Phase 1 Clinical |
Shanghai Simnova Biotechnology Co Ltd |
Glioblastoma |
Details
|
RO-7428731 |
RO-7428731; RG-6156 |
Phase 1 Clinical |
F. Hoffmann-La Roche Ltd |
Glioblastoma |
Details
|
EGFRvIII Targeted Chimeric Antigen Receptor CAR-T Cell Therapy (Chembrain) |
|
Phase 1 Clinical |
Chembrain Ltd |
Glioblastoma; Glioma |
Details
|
hEGFRvIII-CD3 Bi-scFv |
|
Phase 1 Clinical |
Duke University |
Glioblastoma; Glioma |
Details
|
GNC-039 |
GNC-039 |
Phase 1 Clinical |
|
Solid tumours; Hematologic Neoplasms; Glioma; Neoplasm Metastasis |
Details
|
Etevritamab |
AMG-596 |
Phase 1 Clinical |
Amgen Inc |
Glioblastoma |
Details
|
Anti-EGFRvIII-CAR |
EGFRvIII CAR; Anti-EGFRvIII-CAR |
Phase 2 Clinical |
National Cancer Institute |
Glioblastoma; Brain Neoplasms; Gliosarcoma; Glioma |
Details
|
Recombinant anti-EGFR chimeric monoclonal antibody (Shanghai CP Guojian) |
CPGJ-602; 602; CPGJ602; CPGJ 602 |
Phase 2 Clinical |
Sunshine GuoJian Pharmaceutical (Shanghai) Co Ltd |
Colorectal Neoplasms |
Details
|
WSD-0922 |
WSD-0922; WSD0922 |
Phase 1 Clinical |
Wayshine Biopharm International Ltd |
Glioblastoma; Neoplasms; Astrocytoma; Carcinoma, Non-Small-Cell Lung |
Details
|
EGFRvIII-directed CAR-T cell tharapy (Novartis/University of Pennsylvania) |
LXF-821 |
Phase 1 Clinical |
University Of Pennsylvania, Novartis Pharma Ag |
Glioblastoma |
Details
|
EGFRvIII-CAR |
|
Phase 1 Clinical |
Duke University Medical Center |
Glioblastoma |
Details
|
Autologous Anti-EGFRvIII synNotch Receptor Induced Anti-EphA2/IL-13R alpha2 CAR (E-SYNC) T Cells therapy(California Institute For Regenerative Medicine) |
|
Phase 1 Clinical |
California Institute For Regenerative Medicine, National Cancer Institute |
Glioblastoma |
Details
|
Targeted EGFRvIII autochimeric antigen receptor T cell therapy (DCTY) |
DCTY0801; DCTY-0801 |
Phase 1 Clinical |
Beijing DCTY Biotech Co Ltd |
Glioblastoma |
Details
|
SNC-109 |
SNC109; SNC-109 |
Phase 1 Clinical |
Shanghai Simnova Biotechnology Co Ltd |
Glioblastoma |
Details
|
RO-7428731 |
RO-7428731; RG-6156 |
Phase 1 Clinical |
F. Hoffmann-La Roche Ltd |
Glioblastoma |
Details
|
EGFRvIII Targeted Chimeric Antigen Receptor CAR-T Cell Therapy (Chembrain) |
|
Phase 1 Clinical |
Chembrain Ltd |
Glioblastoma; Glioma |
Details
|
hEGFRvIII-CD3 Bi-scFv |
|
Phase 1 Clinical |
Duke University |
Glioblastoma; Glioma |
Details
|
GNC-039 |
GNC-039 |
Phase 1 Clinical |
|
Solid tumours; Hematologic Neoplasms; Glioma; Neoplasm Metastasis |
Details
|
Etevritamab |
AMG-596 |
Phase 1 Clinical |
Amgen Inc |
Glioblastoma |
Details
|
Anti-EGFRvIII-CAR |
EGFRvIII CAR; Anti-EGFRvIII-CAR |
Phase 2 Clinical |
National Cancer Institute |
Glioblastoma; Brain Neoplasms; Gliosarcoma; Glioma |
Details
|
Recombinant anti-EGFR chimeric monoclonal antibody (Shanghai CP Guojian) |
CPGJ-602; 602; CPGJ602; CPGJ 602 |
Phase 2 Clinical |
Sunshine GuoJian Pharmaceutical (Shanghai) Co Ltd |
Colorectal Neoplasms |
Details
|
WSD-0922 |
WSD-0922; WSD0922 |
Phase 1 Clinical |
Wayshine Biopharm International Ltd |
Glioblastoma; Neoplasms; Astrocytoma; Carcinoma, Non-Small-Cell Lung |
Details
|
EGFRvIII-directed CAR-T cell tharapy (Novartis/University of Pennsylvania) |
LXF-821 |
Phase 1 Clinical |
University Of Pennsylvania, Novartis Pharma Ag |
Glioblastoma |
Details
|
EGFRvIII-CAR |
|
Phase 1 Clinical |
Duke University Medical Center |
Glioblastoma |
Details
|
Autologous Anti-EGFRvIII synNotch Receptor Induced Anti-EphA2/IL-13R alpha2 CAR (E-SYNC) T Cells therapy(California Institute For Regenerative Medicine) |
|
Phase 1 Clinical |
California Institute For Regenerative Medicine, National Cancer Institute |
Glioblastoma |
Details
|
Targeted EGFRvIII autochimeric antigen receptor T cell therapy (DCTY) |
DCTY0801; DCTY-0801 |
Phase 1 Clinical |
Beijing DCTY Biotech Co Ltd |
Glioblastoma |
Details
|
SNC-109 |
SNC109; SNC-109 |
Phase 1 Clinical |
Shanghai Simnova Biotechnology Co Ltd |
Glioblastoma |
Details
|
RO-7428731 |
RO-7428731; RG-6156 |
Phase 1 Clinical |
F. Hoffmann-La Roche Ltd |
Glioblastoma |
Details
|
EGFRvIII Targeted Chimeric Antigen Receptor CAR-T Cell Therapy (Chembrain) |
|
Phase 1 Clinical |
Chembrain Ltd |
Glioblastoma; Glioma |
Details
|
hEGFRvIII-CD3 Bi-scFv |
|
Phase 1 Clinical |
Duke University |
Glioblastoma; Glioma |
Details
|
GNC-039 |
GNC-039 |
Phase 1 Clinical |
|
Solid tumours; Hematologic Neoplasms; Glioma; Neoplasm Metastasis |
Details
|
Etevritamab |
AMG-596 |
Phase 1 Clinical |
Amgen Inc |
Glioblastoma |
Details
|
Anti-EGFRvIII-CAR |
EGFRvIII CAR; Anti-EGFRvIII-CAR |
Phase 2 Clinical |
National Cancer Institute |
Glioblastoma; Brain Neoplasms; Gliosarcoma; Glioma |
Details
|
Recombinant anti-EGFR chimeric monoclonal antibody (Shanghai CP Guojian) |
CPGJ-602; 602; CPGJ602; CPGJ 602 |
Phase 2 Clinical |
Sunshine GuoJian Pharmaceutical (Shanghai) Co Ltd |
Colorectal Neoplasms |
Details
|
WSD-0922 |
WSD-0922; WSD0922 |
Phase 1 Clinical |
Wayshine Biopharm International Ltd |
Glioblastoma; Neoplasms; Astrocytoma; Carcinoma, Non-Small-Cell Lung |
Details
|
EGFRvIII-directed CAR-T cell tharapy (Novartis/University of Pennsylvania) |
LXF-821 |
Phase 1 Clinical |
University Of Pennsylvania, Novartis Pharma Ag |
Glioblastoma |
Details
|
EGFRvIII-CAR |
|
Phase 1 Clinical |
Duke University Medical Center |
Glioblastoma |
Details
|
Autologous Anti-EGFRvIII synNotch Receptor Induced Anti-EphA2/IL-13R alpha2 CAR (E-SYNC) T Cells therapy(California Institute For Regenerative Medicine) |
|
Phase 1 Clinical |
California Institute For Regenerative Medicine, National Cancer Institute |
Glioblastoma |
Details
|
Targeted EGFRvIII autochimeric antigen receptor T cell therapy (DCTY) |
DCTY0801; DCTY-0801 |
Phase 1 Clinical |
Beijing DCTY Biotech Co Ltd |
Glioblastoma |
Details
|
SNC-109 |
SNC109; SNC-109 |
Phase 1 Clinical |
Shanghai Simnova Biotechnology Co Ltd |
Glioblastoma |
Details
|
RO-7428731 |
RO-7428731; RG-6156 |
Phase 1 Clinical |
F. Hoffmann-La Roche Ltd |
Glioblastoma |
Details
|
EGFRvIII Targeted Chimeric Antigen Receptor CAR-T Cell Therapy (Chembrain) |
|
Phase 1 Clinical |
Chembrain Ltd |
Glioblastoma; Glioma |
Details
|
hEGFRvIII-CD3 Bi-scFv |
|
Phase 1 Clinical |
Duke University |
Glioblastoma; Glioma |
Details
|
GNC-039 |
GNC-039 |
Phase 1 Clinical |
|
Solid tumours; Hematologic Neoplasms; Glioma; Neoplasm Metastasis |
Details
|
Etevritamab |
AMG-596 |
Phase 1 Clinical |
Amgen Inc |
Glioblastoma |
Details
|